相似文献
1
The interplay between eosinophils and T cells in breast cancer immunotherapy.
Mol Oncol. 2023 Apr;17(4):545-547. doi: 10.1002/1878-0261.13413. Epub 2023 Mar 17.
2
IL-5-producing CD4 T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
Cancer Cell. 2023 Jan 9;41(1):106-123.e10. doi: 10.1016/j.ccell.2022.11.014. Epub 2022 Dec 15.
3
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.
Oncoimmunology. 2020 Feb 15;9(1):1727116. doi: 10.1080/2162402X.2020.1727116. eCollection 2020.
4
Eosinophils in the tumor microenvironment: implications for cancer immunotherapy.
J Transl Med. 2023 Aug 16;21(1):551. doi: 10.1186/s12967-023-04418-7.
5
T cell-eosinophil crosstalk-A new road for effective immune checkpoint blockade in breast cancer?
Cancer Cell. 2023 Jan 9;41(1):9-11. doi: 10.1016/j.ccell.2022.11.008. Epub 2022 Dec 15.
6
Crosstalk between IL-15Rα tumor-associated macrophages and breast cancer cells reduces CD8 T cell recruitment.
Cancer Commun (Lond). 2022 Jun;42(6):536-557. doi: 10.1002/cac2.12311. Epub 2022 May 25.
7
Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.
Nat Immunol. 2022 Sep;23(9):1309-1316. doi: 10.1038/s41590-022-01291-2. Epub 2022 Aug 24.
8
Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model.
Asian Pac J Cancer Prev. 2014;15(1):265-71. doi: 10.7314/apjcp.2014.15.1.265.
9
PTPRO-related CD8 T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer.
Front Immunol. 2022 Aug 8;13:947841. doi: 10.3389/fimmu.2022.947841. eCollection 2022.
10
Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
J Transl Med. 2022 Dec 23;20(1):615. doi: 10.1186/s12967-022-03807-8.
引用本文的文献
1
Targeting of the IL-33/Wnt axis restricts breast cancer stemness and metastasis.
Sci Rep. 2025 May 25;15(1):18172. doi: 10.1038/s41598-025-03260-9.
2
Identification of prognostic biomarker of non-small cell lung cancer based on mitochondrial permeability transition-driven necrosis-related genes and determination of anti-tumor effect of ARL14.
Hereditas. 2025 Feb 3;162(1):16. doi: 10.1186/s41065-025-00379-7.
3
Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA-Seq and Bulk RNA-Seq: A Model Development and Validation Study.
Cancer Med. 2025 Jan;14(2):e70617. doi: 10.1002/cam4.70617.
4
Interventional Effect of Donkey Bone Collagen Peptide Iron Chelate on Cyclophosphamide Induced Immunosuppressive Mice.
Nutrients. 2024 Jul 25;16(15):2413. doi: 10.3390/nu16152413.
5
Decoding the IL-33/ST2 Axis: Its Impact on the Immune Landscape of Breast Cancer.
Int J Mol Sci. 2023 Sep 13;24(18):14026. doi: 10.3390/ijms241814026.
6
Interleukin-33: Friend or Foe in Gastrointestinal Tract Cancers?
Cells. 2023 May 26;12(11):1481. doi: 10.3390/cells12111481.
本文引用的文献
1
IL-5-producing CD4 T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
Cancer Cell. 2023 Jan 9;41(1):106-123.e10. doi: 10.1016/j.ccell.2022.11.014. Epub 2022 Dec 15.
2
Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.
Nat Immunol. 2022 Sep;23(9):1309-1316. doi: 10.1038/s41590-022-01291-2. Epub 2022 Aug 24.
3
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
JCO Precis Oncol. 2022 Jul;6:e2100413. doi: 10.1200/PO.21.00413.
4
Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
Immunotherapy. 2022 Mar;14(4):189-199. doi: 10.2217/imt-2021-0149. Epub 2022 Jan 5.
5
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.
Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8. doi: 10.1016/j.ccell.2021.09.010. Epub 2021 Oct 14.
6
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Nat Commun. 2021 Sep 21;12(1):5563. doi: 10.1038/s41467-021-25769-z.
7
Refining patient selection for breast cancer immunotherapy: beyond PD-L1.
ESMO Open. 2021 Oct;6(5):100257. doi: 10.1016/j.esmoop.2021.100257. Epub 2021 Sep 3.
8
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
9
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Nat Med. 2021 May;27(5):820-832. doi: 10.1038/s41591-021-01323-8. Epub 2021 May 6.
10
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
Zotero 插件